American Society of Hirudotherapy

WP-EAGSAKELEGDPVAG

Whitmania pigra-derived 15-residue anti-atherosclerosis peptide — Hu 2020 demonstrates inhibition of macrophage migration via JNK + p38 MAPK pathways.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 27, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • Leech Thrombospondin-Like Protein50 kDa
  • WP-EAGSAKELEGDPVAG1.5 kDa
Molecular weight (kilodaltons) of WP-EAGSAKELEGDPVAG (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
In vitro
Drug vs leech
Purified natural compound

Clinical translation limit

WP-EAGSAKELEGDPVAG's in vitro macrophage anti-migration activity does NOT establish clinical anti-atherosclerosis efficacy. No FDA-approved derivative exists; W. pigra is a non-hematophagous TCM leech, not the FDA-cleared K040187 medicinal leech.

Molecular Profile

Category
Anti-inflammatory
Evidence tier
Preclinical
Molecular weight
1,480 Da
Source species
Whitmania pigra
Discovered
2020 · Hu B et al.

Biological Targets

  • → macrophage migration
  • → JNK pathway
  • → p38 MAPK pathway
  • → MEKK4 / ASK2 signaling

Key Citations

  1. Hu B et al. (2020), J Ethnopharmacol · PMID 32119950

External Resources

    Related Anti-inflammatory Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.